Greiner et al. demonstrated that mutant NPM1 is immunogenic with T cells from the peripheral blood of patients with NPM1-mutant AML reacting in vitro to specific peptides derived from the mutant NPM1 (142). This evidence concerns the gene NPM1 and acute myeloid leukemia.